Molecular Partners
| Company type | Public |
|---|---|
| SIX: MOLN Nasdaq: MOLN | |
| Industry | Biotechnology |
| Founded | 2004 |
| Headquarters | Schlieren, canton of Zürich, Switzerland |
Key people |
|
| Total assets | CHF 145.6 million (Mar. 31, 2021) |
Number of employees | 152 FTE (Mar. 31, 2021) |
| Website | molecularpartners |
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.